产品
编 号：F352936
分子式：C14H11Cl3N2O3
分子量：361.61
分子式：C14H11Cl3N2O3
分子量：361.61
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
600
In-stock
10mg
1040
In-stock
50mg
3600
In-stock
100mg
5451
In-stock
结构图
CAS No: 415713-60-9
产品详情
生物活性：
RI-1 is a RAD51 inhibitor, with IC50s ranging from 5 to 30 μM. RI-1 binds covalently to the surface of RAD51 protein at cysteine 319. RI-1 inactivates RAD51 by directly binding to a protein surface that serves as an interface between protein subunits in RAD51 filaments. RI-1 can disrupt homologous recombination in human cells.
体内研究：
RI-1 (50 mg/kg; i.p. every 3 d for 30 d) significantly reduces triple negative breast cancer (TNBC) tumor growth in mice.Animal Model:Female BALB/c nude mice (6 weeks) bearing TNBC tumor
Dosage:50 mg/kg
Administration:I.p. every 3 days for 30 days
Result:Resulted in significant inhibition of tumor growth.Did not cause body weight loss significantly.
体外研究：
RI-1 (1-50 μM; 24 h) specifically inhibits homologous recombination (HR) in U2OS cells and stimulates single-strand annealing (SSA) in HEK293 cells.?RI-1 (5-20 μM; 30 min) inhibits HsRAD51 in a concentration-dependent manner.?RI-1 (20 μM; 8 h) disrupts the formation of RAD51 foci after DNA damage in immortalized human fibroblasts.?RI-1 (15-25 μM; 24 h) sensitizes human cancer cells (HeLa, MCF-7 and U2OS) to cross-linking chemotherapy.
RI-1 is a RAD51 inhibitor, with IC50s ranging from 5 to 30 μM. RI-1 binds covalently to the surface of RAD51 protein at cysteine 319. RI-1 inactivates RAD51 by directly binding to a protein surface that serves as an interface between protein subunits in RAD51 filaments. RI-1 can disrupt homologous recombination in human cells.
体内研究：
RI-1 (50 mg/kg; i.p. every 3 d for 30 d) significantly reduces triple negative breast cancer (TNBC) tumor growth in mice.Animal Model:Female BALB/c nude mice (6 weeks) bearing TNBC tumor
Dosage:50 mg/kg
Administration:I.p. every 3 days for 30 days
Result:Resulted in significant inhibition of tumor growth.Did not cause body weight loss significantly.
体外研究：
RI-1 (1-50 μM; 24 h) specifically inhibits homologous recombination (HR) in U2OS cells and stimulates single-strand annealing (SSA) in HEK293 cells.?RI-1 (5-20 μM; 30 min) inhibits HsRAD51 in a concentration-dependent manner.?RI-1 (20 μM; 8 h) disrupts the formation of RAD51 foci after DNA damage in immortalized human fibroblasts.?RI-1 (15-25 μM; 24 h) sensitizes human cancer cells (HeLa, MCF-7 and U2OS) to cross-linking chemotherapy.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备